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Abstract
Introduction: Endotracheal intubation in the ICU is associated with a high incidence of complications. Etomidate
use is debated in septic shock because it increases the risk of critical illness-related corticosteroid insufficiency,
which may impact outcome. We hypothesized that hydrocortisone, administered in all septic shock cases in our
ICU, may counteract some negative effects of etomidate.
The aim of our study was to compare septic shock patients who received etomidate versus another induction drug
both for short-term safety and for long-term outcomes.
Methods: A single-center observational study was carried out in septic shock patients, treated with hydrocortisone
and intubated within the first 48 hours of septic shock. Co-primary end points were life-threatening complications
incidence occurring within the first hour after intubation and mortality during the ICU stay. Statistical analyses
included unmatched and matched cohorts using a propensity score analysis. P < 0.05 was considered significant.
Results: Sixty patients in the etomidate cohort and 42 patients in the non-etomidate cohort were included. Critical
illness-related corticosteroid insufficiency was 79% in the etomidate cohort and 52% in the non-etomidate cohort (P =
0.01). After intubation, life-threatening complications occurred in 36% of the patients whatever the cohort. After
adjustment with propensity score analysis, etomidate was a protective factor for death in the ICU both in unmatched
(hazard ratio, 0.33 (0.15 to 0.75); P < 0.01)) and matched cohorts (hazard ratio, 0.33 (0.112 to 0.988); P = 0.04).
Conclusion: In septic shock patients treated with hydrocortisone, etomidate did not decrease life-threatening
complications following intubation, but when associated with hydrocortisone it also did not impair outcome.
Introduction
Endotracheal intubation, one of the most commonly per-
formed procedures in the ICU [1-3], is associated with a
high incidence of early onset life-threatening complications
(25 to 39%) because of the precarious hemodynamic and
respiratory status of those patients [1,2,4]. To limit intuba-
tion-related life-threatening complications, bundle therapy
including hemodynamically well-tolerated anesthetics such
as etomidate has been suggested in the ICU [1,5] and is
widely used in prehospital or emergency room environ-
ments [6,7]. In critically ill patients, the use of etomidate
has been challenged because it inhibits adrenocortical ster-
oid synthesis by reversibly blocking the 11b-hydroxylase
enzyme action [8-10] for at least 24 hours after a single
bolus [9,11]. This inhibition is associated with a risk of
reversible failure of the adrenal axis, which can lead to cri-
tical illness-related corticosteroid insufficiency (CIRCI)
[12]. Because CIRCI is associated with an increased mor-
tality in septic shock patients [8,13-15], etomidate use is
controversial in this setting [16-19]. Moreover, some stu-
dies suggest a link between etomidate and poor outcome
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[11,13,14,20-22] but others failed to confirm this link
[6,23-25].
To limit the potential consequences of etomidate on
the adrenal axis, hydrocortisone administration may be
of interest. To our knowledge, only one randomized con-
trolled clinical trial, performed in nonseptic critically ill
patients, failed to demonstrate any benefit to counteract
etomidate’s side effect using a short course (48 hours) of
hydrocortisone treatment [10]. In our ICU, the anesthesia
bundle for intubation strongly recommends the use of a
rapid sequence induction [5] and our septic shock bundle
therapy includes hydrocortisone for all septic shock
patients after a cosyntropin test as is frequently observed
and suggested in France [15,26,27]. In our operating
room, no local bundle is purposed, although ketamine
and etomidate are suggested for critically ill patients.
Because of its potential protective effect on intubation
safety [3-5,7], due to its cardiovascular properties, and its
deleterious impact on adrenal gland physiology [8,28],
etomidate may have contrasting impact on the incidence
of life-threatening complications occurring within 1 hour
after intubation and on the long-term outcome in septic
shock patients.
The present study was aimed at assessing the short-term
safety and the long-term outcomes of septic patients trea-
ted with etomidate versus another induction drug for intu-
bation. We designed the present propensity-score-driven
study to evaluate, in septic shock patients, first the inci-
dence of immediate life-threatening complications after
intubation and second the long-term outcome according
to the hypnotic used. The propensity score allowed us to
match patients according to their probably to receive eto-
midate or not and to adjust for confounding factors in the
present observational study.
Materials and methods
Study setting and patients
A cohort, observational study was performed in an adult
ICU of a university hospital from June 2006 until Decem-
ber 2009. Data were extracted from prospective studies
conducted in our ICU and previous databases [1,2,5,15,26].
The study was approved by the local ethics committee
(Comité de Gestion et d’Organisation de l’Anesthésie Réa-
nimation, Montpellier University Hospital) and, in accor-
dance with French law, informed consent was waived. We
adhered to the Strengthening the Reporting of Observa-
tional Studies in Epidemiology guidelines [29].
Etomidate blocks cortisol synthesis primarily by inhi-
biting the activity of 11b-hydroxylase for at least 24 to 48
hours [10,30]. Therefore, to describe the potential impact
of etomidate on early and late outcome in septic shock
patients, consecutive patients were eligible if they had
received an induction agent for endotracheal intubation
within the first 48 hours of septic shock onset. Patients
were treated according to international guidelines for
management of severe sepsis and septic shock [31] but all
received hydrocortisone [15]. Exclusion criteria included
pregnancy, age < 18 years, moribund patients, immuno-
suppression, and long-term or short-term corticosteroid
treatment within the past 4 weeks. A cosyntropin stimula-
tion test with 250 μg cosyntropin was performed in all
septic shock patients. A 50 mg intravenous bolus of hydro-
cortisone was then administered every 6 hours, beginning
within the first 12 hours of septic shock, for at least 5days,
tapered and stopped in 5 days according to the reversal of
shock. Patients were grouped as those having received eto-
midate for intubation (etomidate cohort) versus those sub-
jects having received another hypnotic (non-etomidate
cohort).
Definitions
Septic shock was defined by evidence of infection and a sys-
temic response to infection, in addition to systolic blood
pressure < 90 mmHg, despite adequate fluid replacement,
or a need for vasopressors for at least 1 hour, according
to the American College of Chest Physicians/Society of
Critical Care Medicine Consensus Conference Committee
criteria [32]. Nonresponse to the cosyntropin stimulation
test using an immunoradiology assay (SP2100; Beckman-
coulter SAS, Roissy, France) was defined by a delta cortisol
(60 minutes after 250 μg cosyntropin) < 9 μg/dl [15,26,28].
CIRCI was defined by a delta cortisol (60 minutes after 250
μg cosyntropin) < 9 μg/dl or a baseline plasma cortisol level
< 10 μg/l [12].
Data collection
A standardized data collection instrument and guidance
tool was developed for data collection. Record review and
data extraction were performed by a single investigator
(NC) and regular meetings were conducted to address
any problems encountered during the data collection
phase according to the recommendations that have been
published to minimize validity threats in chart review
studies [33]. Upon ICU admission, the baseline character-
istics and the main variables obtained before intubation
were recorded either by a nurse (from June 2006 to Jan
2009) or by computer-driven software plugged to the
monitor, which recorded automatically all the variables.
At the time of intubation, clinical data including reason
for intubation, interventions including sedative agent used,
need for and doses of vasopressors were recorded. During
the intubation procedure, drug administration and the dif-
ficulty to intubate rate (defined by three or more attempts
at laryngoscopy to place the endotracheal tube into the
trachea and/or > 10 minutes using conventional laryngo-
scopy and/or the need for another operator) [5] were
documented. Within the first hour after intubation we
recorded the short-term life-threatening complications
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that occurred, defined as previously reported [2,5]: cardiac
arrest, severe cardiovascular collapse (defined as systolic
blood pressure < 65 mmHg recorded at least once and/or
< 90 mmHg that lasted 30 minutes despite 500 to 1,000 ml
fluid loading and/or requiring introduction of vasoactive
support) and severe hypoxia (defined as a decrease in SpO2
level < 80% during attempts). Patients who already pre-
sented a cardiovascular collapse after fluid loading or who
were severely hypoxemic (SpO2 < 80%) after preoxygena-
tion by noninvasive positive-pressure ventilation were not
considered to have had an intubation-related complication,
but rather to have presented a life-threatening condition
requiring an emergency endotracheal intubation.
During the ICU stay, we documented the results for
basal plasma cortisol and that after the cosyntropin test, as
well as total amounts and durations of hydrocortisone and
vasopressor treatments from day 0 to day 5. Outcome data
include the duration of shock, length of mechanical venti-
lation, nosocomial infection incidence, ICU and hospital
lengths of stay, and day-28 mortality.
Statistical analysis
We had sufficient resources to review 102 patients in
total. Descriptive data of quantitative variables were sum-
marized as the mean ± standard deviation or median
with interquartile range, according to the normality of
the distribution, assessed with the Shapiro-Wilk test and
compared with the Mann-Whitney or t test. Categorical
data were expressed as the number and percentage and
were compared with a chi-square analysis.
Using two statistical methods, we assessed the occur-
rence of short-term life-threatening complications and
the long-term outcomes according to the administration
of etomidate versus another hypnotic drug. First, unad-
justed differences between patients receiving etomidate
or not were compared using logistic regression after cali-
bration with the Hosmer-Lemeshow wellness-of-fit test.
Furthermore, long-term survival was assessed by a Cox
regression in which we included all variables associated
with P < 0.20 in the univariate analysis. A stepwise proce-
dure then allowed the final multivariate model to be
obtained.
Second, since patients were not randomly assigned to
etomidate or other hypnotic in this observational study,
we developed a propensity score using all variables asso-
ciated with P < 0.20 in the univariate analysis. The propen-
sity score is defined as a subject’s probability of receiving a
specific treatment (for example, etomidate) conditional on
the observed covariates, and thus controls for selection
bias in observational studies [34]. For the coupling process,
optimal one-to-one nearest neighbor matching was used.
When needed, patients already matched were replaced by
the closest one in the in the propensity score. P < 0.05 was
considered significant. Statistical analysis was performed




During the study period, among 1,632 patients admitted to
the ICU, 331 presented septic shock during their stay.
Among these 331 patients, 229 either developed septic
shock > 48 hours after intubation, did not have a cosyntro-
pin test or data could not be extracted from the charts.
Thus, 102 patients meeting the inclusion criteria were
analyzed; 60 in the etomidate cohort and 42 in the non-
etomidate cohort. The hypnotics used to induce anesthesia
for intubation in the non-etomidate cohort were ketamine
(n = 18), propofol (n = 10), thiopental (n = 13) or none (n =
1). The nonabdominal source of sepsis, higher Simplified
Acute Physiology Score II [35] and Sequential Organ Failure
Assessment [36] severity scores were more frequently
observed in the etomidate cohort (Table 1).
We first evaluated the association of hypnotics, intuba-
tion-related life-threatening complications and outcome
in unmatched cohorts.
Intubation procedure and intubation-related
complications
Intubation was indicated mainly for urgent surgery (42%)
or acute respiratory failure (35%). Myorelaxants were
used in nearly all of the procedures without any compli-
cations related to their use (Table 1). Intubation was dif-
ficult in 10 cases (10%), independent of the administered
hypnotic. Short-term life-threatening complications
within 1 hour of intubation occurred in 37 (36%) of the
102 studied patients (Figure 1). In univariate analysis, the
Simplified Acute Physiology Score II was associated with
a higher risk of complications and both the administra-
tion of norepinephrine prior to intubation and the use of
a drug other than etomidate to facilitate intubation were
associated with a lower risk of complications (Table 2).
In multivariate analysis, the administration of norepi-
nephrine prior to intubation was the sole independent
protective factor for life-threatening complications occur-
ring after intubation (Table 2).
Critical illness-related corticosteroid insufficiency and
hydrocortisone treatment
Patients were compared according to the hypnotic they
received to facilitate intubation. The cosyntropin test was
performed within 24 hours after intubation in 85% of the
patients, and after the first 24 hours in 15% of the popula-
tion but always before the first dose of hydrocortisone.
Hydrocortisone treatment was started 540 (300 to 1,125)
minutes after intubation. The basal plasma cortisol con-
centration was significantly lower (19 (14 to 35) μg/dl ver-
sus 31 (17 to 45) μg/dl; P = 0.04) and the percentage of
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nonresponders to the cosyntropin stimulation test was sig-
nificantly higher (79% vs. 52%; P = 0.01) in the etomidate
cohort compared with the non-etomidate cohort. CIRCI
was also significantly more frequently observed in the eto-
midate cohort compared with the non-etomidate cohort
(79% vs. 59%; P = 0.04). In the etomidate cohort, the cumu-
lative hydrocortisone dose was significantly higher (1,250
(650 to 1,650) mg vs. 750 (350 to 1,150) mg; P = 0.02) and
the duration of treatment was significantly longer (168 (96
to 216) hours vs. 96 (48 to 162) hours; P = 0.01) than in the
non-etomidate cohort.
Reversal of shock
Norepinephrine was administered within 12 hours after
intubation in 100% of the patients without significant dif-
ference between cohorts. Patients in the etomidate cohort
needed a higher cumulative dose of norepinephrine during
their ICU stay compared with patients anesthetized with
another hypnotic (95 (39 to 203) mg vs. 58 (30 to 97) mg
from day 0 to day 5; P = 0.02). The duration of norepi-
nephrine treatment was not different between cohorts (58
(37 to 94) hours in the etomidate cohort vs. 48 (25 to 81)
hours in the non-etomidate cohort; P = 0.20).
ICU length of stay and complications
The incidence of nosocomial infections, length of
mechanical ventilation, and lengths of ICU and hospital
stay did not significantly differ between cohorts (Table 3).
Mortality
Although the crude day-28 mortality was not different
according to the drug used to facilitate intubation, the Cox
regression model yielded a hazard ratio for death at day 28
in the etomidate cohort, as compared with the non-etomi-
date cohort, of 0.33 (0.12 to 0.90; P = 0.03) (Table 4). The
Hosmer-Lemeshow test showed that the model fits to
Table 1 Baseline characteristics of the 102 studied patients
Characteristic All patients (n = 102) Etomidate cohort (n = 60) Non-etomidate cohort (n = 42) P value
Age (years) 69 (58 to 75) 71 (62 to 72) 68 (56 to 73) 0.18
Male gender 72 (71) 44 (73) 28 (67) 0.002
Body mass index (kg/m2) 25 (23 to 30) 25 (23 to 29) 26 (24 to 32) 0.31
SAPS II upon ICU admission 48 (40 to 63) 52 (42 to 65) 46 (34 to 58) 0.049
SOFA score upon ICU admission 8 (6 to 12) 10 (7 to 13) 8 (6 to 11) 0.04
Previous disease
Hypertension 43 (42) 26 (43) 17 (41) 0.77
Coronary artery disease 22 (22) 14 (23) 8 (19) 0.04
Congestive heart failure 29 (28) 17 (27) 12 (29) 0.98
Neurological disease 20 (20) 11 (18) 9 (21) 0.70
Chronic obstructive pulmonary disease 18 (18) 10 (17) 8 (19) 0.76
Diabetes mellitus 20 (20) 10 (17) 10 (24) 0.37
Cancer 41 (40) 26 (43) 15 (36) 0.44
Liver cirrhosis 22 (21) 14 (23) 8 (19) 0.61
Admitting diagnosis group
Medical 42 (41) 27 (45) 15 (36) 0.35
Emergency surgery 45 (44) 23 (38) 22 (52) 0.16
Elective surgery 15 (15) 10 (17) 5 (12) 0.55
Time from infection diagnostic to surgery (hours) 8 (4 to 24) 8 (5 to 24) 8 (4 to 24) > 0.99
Source of sepsis
Pulmonary 33 (32) 21 (35) 12 (29) 0.49
Abdominal 54 (53) 25 (42) 29 (69) 0.02
Other 15 (15) 14 (23) 1 (2) 0.03
Appropriateness of initial antibiotic therapy 68/89 (76) 39/52 (75) 29/37 (78) 0.71
Main variables obtained before intubation
Systolic blood pressure < 90 mmHg 22(39) 15 (45) 7 (29) 0.31
SpO2 below 80% 6 (10) 5 (15) 1 (4) 0.21
Lactatemia (mmol/l) 2.5 (1.1 to 4.7) 2.5 (1.1 to 5.3) 2.3 (1.4 to 4.1) 0.80
Vasopressors use 21 (21) 16 (27) 5 (12) 0.09
Myorelaxant use to facilitate intubation 97 (98) 57 (95) 40 (98) 0.96
Data presented as number (%) or median (quartiles). Appropriateness of initial antibiotic therapy was expressed as the number of appropriate first-line antibiotic
therapies over the number of charts that were exploitable. SAPS II, Simplified Acute Physiology Score II [35]; SOFA, Sequential Organ Failure Assessment [36].
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predict mortality, with 82% of well-classed patients and P =
0.16. Second, we evaluated the association of hypnotics and
both intubation-related life-threatening complications and
outcome in matched cohorts. Propensity score matching
resulted in a cohort of 56 patients, with 28 patients who
received etomidate and 28 patients who did not receive eto-
midate. In this cohort of 56 patients, matching was based
on etomidate use, the Simplified Acute Physiology Score II
score without counting age and the basal plasma cortisol
level. The occurrence of intubation-related life-threatening
complications was similar in both the etomidate and the
non-etomidate cohorts. The Kaplan-Meier estimator for
28-day mortality using propensity score matching was sig-
nificantly lower in the etomidate cohort than in the non-
etomidate cohort and showed a hazard ratio for death in
the ICU in the etomidate cohort, as compared with the
non-etomidate cohort, of 0.33 (0.112 to 0.988) (Figure 2).
The c-statistic for the propensity score was 0.7794.
Discussion
The results of our study show that, first, intubation in
septic shock patients was associated with a 36% rate of
short-term life-threatening complications and that this
rate was independent of the hypnotic used to facilitate
the procedure. Second, to our surprise, in unmatched
cohorts and after matching using a propensity score ana-
lysis, the administration of a single dose of etomidate in
septic shock patients treated with hydrocortisone was
associated with a lower risk of day-28 mortality (Table 3).
Potential confounding factors of the study must be
addressed. First, this study was a single-center observational
study in which the hypnotic used for induction of anesthe-
sia was not randomized. Second, this was a small study sub-
ject to unmeasured or residual confounding (for example,
patient heterogeneity, heterogeneity for intubation indica-
tion, protocol deviation), which is a limitation. The propen-
sity score, however, is a tool to increase the accuracy of
results in cohort studies [37,38]. Moreover, external validity
of observational studies may be higher than for randomized
controlled trials. Third, because of the study design, we
cannot provide detailed explanations about the protective
mechanisms of etomidate on long-term outcomes.
In the present study, the hypnotic used to facilitate















































Figure 1 Incidence of life-threatening complications according to the hypnotic used to facilitate intubation. No difference in life
threatening complications rates was found between the hypnotic used. NS, not significant.
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to limit the risk of cardiovascular collapse that may occur
after intubation [5]. Propofol or pentobarbital represented
20% of the administered hypnotics (Table 2), mainly in the
operating room for urgent surgery. The difficult intubation
rate was high (near 10%), which is above the usual rate in
the operating room but is similar to the rate reported in
the few studies existing in this field [2,5]. To facilitate intu-
bation, almost all of the patients received a myorelaxant
agent (Table 1), mostly succinylcholine, as recommended
by our local protocol. Interestingly, the short-term life-
threatening complications that occurred within 1 hour
after intubation concerned 36% of the patients. This rate is
similar to that in the literature [2,4] and above the rate we
reported after the implementation of a care bundle in non-
selected critically ill patients [5]. The discrepancy between
the present study and our previous results [5] may be
explained by the severity of the patients in the present
study, all of them intubated with cardiovascular instability
related to sepsis. In the multivariate analysis, the sole fac-
tor associated with short-term outcome was the adminis-
tration, prior to intubation, of norepinephrine (Table 2).
Norepinephrine administration before intubation may be
protective by both limiting the risk of severe cardiovascu-
lar collapse following sympatholysis induced by the hypno-
tic and the detrimental effect of thoracic positive pressure
on venous return. In our unit, norepinephrine prior to
induction is suggested for diastolic blood pressure < 45 to
50 mmHg [5].
In the present study, we assessed the short-term life-
threatening complication rate, but also the long-term effect
of hypnotics on outcome. Patients intubated with etomi-
date were more likely to present CIRCI (Table 4) and
needed a longer hydrocortisone treatment and a higher
total amount of hydrocortisone. One bolus of etomidate
Table 2 Comparison of main variables obtained before intubation according to occurrence of a short-term life-
threatening complication
Univariate analysis Multivariate analysis
No life-threatening
complications following
intubation (n = 65)
Life-threatening
complications following
intubation (n = 37)
P value Odds ratio
(95% CI)
P value
SAPS II upon ICU admission 48 (37 to 59) 54 (44 to 70) < 0.01 1.04 (0.99 to
1.08)
0.08
SOFA score upon ICU admission 8 (6 to 12) 8 (6 to 11) 0.75
Main variables obtained before intubation
Lactatemia (mmol/l) 2.6 (1.1 to 4.9) 2.2 (1.5 to 3.9) 0.89
Vasopressors use 19 (29) 2 (6) < 0.01 0.11 (0.01 to
0.93)
0.04
Lowest systolic blood pressure recorded within 30
minutes before intubation (mmHg)
89 (80 to 120) 100 (90 to 122) 0.08 1.01 (0.99 to
1.03)
0.09
Drug used to facilitate intubation
Etomidate 35 (53) 25 (69) 0.18
Other 31 (47) 11 (31) 0.05 0.60 (0.18 to
2.03)
0.41
Myorelaxants 62 (95) 35 (97) 0.86
Data presented as number (%) or median (quartiles). Multivariate analysis was performed using a logistic regression, which assesses the risk of life-threatening
complication within the first hour after intubation. Each variable with P < 0.20 in the univariate analysis was entered in the model. Lowest systolic blood pressure
before intubation, according to its median value, was forced into this model. CI, confidence interval; SAPS II, Simplified Acute Physiology Score II [35]; SOFA,
Sequential Organ Failure Assessment [36].
Table 3 Long-term outcome according to the hypnotic used to facilitate intubation
Etomidate cohort (n = 60) Non-etomidate cohort (n = 42) P value
Number of nosocomial infections 38 (100) 22 (100) 0.84
Pneumonia 20 (53) 10 (45) 0.30
Urinary tract infections 10 (26) 7 (32) > 0.99
Central venous catheter-related infections 8 (21) 5 (23) 0.81
Length of mechanical ventilation (days) 5 (2 to 14.8) 5 (1 to 7) 0.10
ICU length of stay (days) 12 (6 to 22) 9 (4 to 13) 0.06
Hospital length of stay (days) 32 (22 to 50) 29 (19 to 45) 0.18
Mortality at day 28 17 (28) 14 (33) 0.59
Data presented as number (%) or median (quartiles). Nosocomial infections are expressed as the total number during the ICU stay and results are expressed as
the percentage of total nosocomial infections that came out during the ICU stay. Patients could develop more than one infection during the ICU stay.
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impairs cortisol secretion [8,9,39,40] by the inhibition, for
at least 24 to 48 hours, of 11b-hydroxylase, the enzyme
that converts 11b-deoxycortisol to cortisol in critically ill
patients [8,10,21]. The higher rate of CIRCI when patients
received etomidate may explain the higher cumulative dose
of hydrocortisone because, in the present study, hydrocor-
tisone was tapered and stopped according to the reversal of
shock. CIRCI is associated with increased morbidity and
mortality in septic shock patients [8,13,14,22]. However,
despite a higher rate of CIRCI, we showed that etomidate
was a protective factor for mortality in both unmatched
and matched cohorts (Figure 2).
Our study provides new data on the effect of etomidate
in septic shock. In a post-hoc analysis of a multiple-center
trial designed to evaluate the impact of hydrocortisone
treatment in septic shock patients, the authors reported
an increased death rate in patients that had been intu-
bated with etomidate compared with other hypnotics
[28]. In contradiction, this increase was not statistically
significant after adjustment in a multivariate analysis
[21]. Furthermore, Cuthbertson and colleagues showed
that administration of etomidate was associated with
increased mortality, but in only one of two multiple
regression models [20]. Despite higher severity of illness
scores in patients intubated with etomidate compared
with patients intubated with another hypnotic (Table 1),
our study demonstrated a protective effect of etomidate
on day-28 mortality using Cox regression. This effect was
confirmed after matching (Figure 2).
The consequences of etomidate on long-term out-
comes in the present study must be discussed in light of
the co-administration of hydrocortisone. In the present
study, hydrocortisone treatment was started within the
first 12 hours after etomidate administration, earlier than
in other studies [28]. To date, studies have failed to
demonstrate an improved outcome when supplementing
etomidate treatment with corticosteroids [10,22,24] and
hydrocortisone is not recommended in every patient pre-
senting septic shock but is suggested in those refractory
to fluid challenge and dependent on high-dose vasopres-
sors [12]. However, because the inhibition of cortisol
synthesis due to etomidate is immediate, hydrocortisone
must be administered immediately after an etomidate
bolus to counter its effects on steroid synthesis [20]. Eval-
uating the role of hydrocortisone in patients who
received etomidate may thus be interesting. To explain
the impact of etomidate, it has also been reported that
ketamine - which was the main drug used in the non-eto-
midate cohort - may have an anti-inflammatory effect in
experimental sepsis models [41,42]. Whether this anti-
inflammatory effect may exacerbate late sepsis-induced
immunosuppression, however, is unknown.
Conclusion
We have reported that etomidate use for intubation in
septic shock patients treated with hydrocortisone did not
prevent short-term life-threatening complications follow-
ing intubation despite its cardiovascular tolerance profile.
Our study also suggests that patients co-treated with eto-
midate and hydrocortisone might not be associated with
a worse outcome than another hypnotic used to facilitate
intubation. Future randomized controlled studies should
be performed to confirm this result and to evaluate early
hydrocortisone treatment in septic shock patients who
received etomidate.
Key messages
• In septic shock patients treated with hydrocortisone,
despite its cardiovascular tolerance, etomidate was not
Table 4 Comparison of main variables before intubation and cosyntropin test results between day-28 survivors and
nonsurvivors
Multivariate analysis
Survivors (n = 66) Nonsurvivors (n = 36) P value Hazard ratio (95% CI) P value
SAPS II upon ICU admission 45 (37 to 55) 60 (47 to 71) < 0.01 1.04 (1.01 to 1.06) < 0.01
SOFA score upon ICU admission 8 (5 to 11) 11 (8 to 13) 0.08 1.01 (0.89 to 1.16) 0.85
Main variables obtained before intubation
Vasopressor use 10 (15) 11 (31) > 0.99
Drug used to facilitate intubation
Etomidate 41 (62) 19 (53) 0.17 0.33 (0.12 to 0.90) 0.03
Other 25 (38) 17 (47) 0.81
Myorelaxants 62 (94) 35 (97) 0.46
Basal cortisol plasma level (μg/dl) 20 (14 to 40) 33 (19 to 49) 0.08 0.99 (0.96 to 1.03) 0.85
Cortisol plasma level after ACTH test (μg/dl) 31 (18 to 44) 35 (21 to 48) 0.54
Cosyntropin test responders 21/59 (36) 4/22 (19) 0.13
Data presented as number (%) or median (quartiles). Multivariate analysis was performed using a Cox regression analysis for mortality. All variables with P < 0.20
in the univariate analysis were entered in the model. ACTH, Adrenocorticotropic hormone; CI, confidence interval; SAPS II, Simplified Acute Physiology Score II
[35]; 95% CI: 95% confidence interval; SOFA, Sequential Organ Failure Assessment [36].
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associated with a decrease of life-threatening complications
following intubation in comparison with other hypnotics.
• Etomidate was associated with a longer period of
shock and higher cumulative dose of hydrocortisone than
patients intubated with another hypnotic.
• Interestingly, patients treated with etomidate and
hydrocortisone presented a lower risk of day-28 mortality,
both in unmatched and matched cohorts and multivariate
analysis.
Abbreviations
CIRCI: critical illness-related corticosteroid insufficiency.
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Figure 2 Kaplan-Meier curves comparing survival probability after propensity score adjustment in etomidate and non-etomidate
cohorts. Etomidate was associated with a significant lower risk of mortality at day 28. HR, hazard ratio.
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